Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Top
Summary
All studies
Exclusions
Mortality
Ventilation
ICU
Hospitalization
Serious outcomes
Recovery
Cases
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Paxlovid  COVID-19 treatment studies for Paxlovid  C19 studies: Paxlovid  Paxlovid   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
Outcomes in COVID-19 paxlovid studies
Outcomes in paxlovid studies. Pfizer has denied access to Paxlovid for an independent RCT [Ledford].
0 0.5 1 1.5+ All studies 35% 16 53,931 Improvement, Studies, Patients Relative Risk Mortality 69% 7 20,927 Ventilation 3% 1 1,780 ICU admission 86% 1 1,145 Hospitalization 59% 8 50,104 Progression 41% 2 4,040 Cases 37% 1 1,971 Viral clearance 18% 6 2,491 RCTs 69% 3 5,201 RCT mortality 90% 2 3,230 Peer-reviewed 34% 11 6,705 Prophylaxis 37% 1 1,971 Early 43% 15 52,052 Late 32% 1 307 Paxlovid for COVID-19 c19early.com/pl Sep 2022 Favorspaxlovid Favorscontrol after exclusions
0 0.5 1 1.5+ ALL STUDIES MORTALITY VENTILATION ICU ADMISSION HOSPITALIZATION PROGRESSION CASES VIRAL CLEARANCE RANDOMIZED CONTROLLED TRIALS RCT MORTALITY PEER-REVIEWED After Exclusions ALL STUDIES All Prophylaxis Early Late Paxlovid for COVID-19 C19EARLY.COM/PL SEP 2022
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Hammond (DB RCT) 96% 0.04 [0.00-0.68] death 0/1,039 12/1,046 Improvement, RR [CI] Treatment Control Wong (PSM) 66% 0.34 [0.23-0.50] death 890 (n) 890 (n) Yip (PSW) 19% 0.81 [0.47-1.39] death/ICU Arbel 65+ 79% 0.21 [0.05-0.82] death Arbel 40-64 -32% 1.32 [0.16-10.8] death Najjar-Debbiny 46% 0.54 [0.39-0.75] severe case Pfizer (DB RCT) 67% 0.33 [0.01-8.13] death 0/576 1/569 Dryden-Peterson 45% 0.55 [0.38-0.80] hosp. 40/6,036 232/24,286 Shao 20% 0.80 [0.71-0.91] viral time 17 (n) 114 (n) OT​1 Li (ES) 79% 0.21 [0.15-0.28] viral+ 18/175 130/224 Lu 12% 0.88 [0.78-0.98] viral+ n/a n/a Ganatra (PSM) 95% 0.05 [0.00-0.81] death 0/1,130 10/1,130 Shao 20% 0.80 [0.71-0.91] viral time 17 (n) 114 (n) OT​1 Zhong 15% 0.85 [0.65-1.13] recov. time 106 (n) 36 (n) Zhou (PSM) 73% 0.27 [0.13-0.58] death 7/2,808 100/10,849 Tau​2 = 0.09, I​2 = 83.2%, p < 0.0001 Early treatment 43% 0.57 [0.46-0.70] 65/12,794 485/39,258 43% improvement Li 32% 0.68 [0.47-0.98] viral+ 40/83 130/224 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.0025 Late treatment 32% 0.68 [0.47-0.98] 40/83 130/224 32% improvement Pfizer (DB RCT) 37% 0.63 [0.40-1.00] cases 986 (n) 985 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.05 Prophylaxis 37% 0.63 [0.40-1.00] 0/986 0/985 37% improvement All studies 35% 0.65 [0.56-0.76] 105/13,863 615/40,467 35% improvement 17 paxlovid COVID-19 studies c19early.com/pl Sep 2022 Tau​2 = 0.05, I​2 = 71.4%, p < 0.0001 Effect extraction pre-specified(most serious outcome) 1 OT: comparison with other treatment Favors paxlovid Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Hammond (DB RCT) 96% 0.04 [0.00-0.68] death 0/1,039 12/1,046 Improvement, RR [CI] Treatment Control Wong (PSM) 66% 0.34 [0.23-0.50] death 890 (n) 890 (n) Yip (PSW) 19% 0.81 [0.47-1.39] death/ICU Arbel 65+ 79% 0.21 [0.05-0.82] death Arbel 40-64 -32% 1.32 [0.16-10.8] death Najjar-Debbiny 46% 0.54 [0.39-0.75] severe case Pfizer (DB RCT) 67% 0.33 [0.01-8.13] death 0/576 1/569 Dryden-Peterson 45% 0.55 [0.38-0.80] hosp. 40/6,036 232/24,286 Li (ES) 79% 0.21 [0.15-0.28] viral+ 18/175 130/224 Lu 12% 0.88 [0.78-0.98] viral+ n/a n/a Ganatra (PSM) 95% 0.05 [0.00-0.81] death 0/1,130 10/1,130 Zhong 15% 0.85 [0.65-1.13] recov. time 106 (n) 36 (n) Zhou (PSM) 73% 0.27 [0.13-0.58] death 7/2,808 100/10,849 Tau​2 = 0.23, I​2 = 85.0%, p < 0.0001 Early treatment 53% 0.47 [0.34-0.66] 65/12,760 485/39,030 53% improvement Li 32% 0.68 [0.47-0.98] viral+ 40/83 130/224 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.0025 Late treatment 32% 0.68 [0.47-0.98] 40/83 130/224 32% improvement Pfizer (DB RCT) 37% 0.63 [0.40-1.00] cases 986 (n) 985 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.05 Prophylaxis 37% 0.63 [0.40-1.00] 0/986 0/985 37% improvement All studies 42% 0.58 [0.46-0.73] 105/13,829 615/40,239 42% improvement 15 paxlovid COVID-19 studies after exclusions c19early.com/pl Sep 2022 Tau​2 = 0.10, I​2 = 74.5%, p < 0.0001 Effect extraction pre-specified(most serious outcome) Favors paxlovid Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Hammond (DB RCT) 96% 0.04 [0.00-0.68] 0/1,039 12/1,046 Improvement, RR [CI] Treatment Control Wong (PSM) 66% 0.34 [0.23-0.50] 890 (n) 890 (n) Arbel 65+ 79% 0.21 [0.05-0.82] Arbel 40-64 -32% 1.32 [0.16-10.8] Pfizer (DB RCT) 67% 0.33 [0.01-8.13] 0/576 1/569 Ganatra (PSM) 95% 0.05 [0.00-0.81] 0/1,130 10/1,130 Zhou (PSM) 73% 0.27 [0.13-0.58] 7/2,808 100/10,849 Tau​2 = 0.02, I​2 = 4.8%, p < 0.0001 Early treatment 69% 0.31 [0.21-0.44] 7/6,443 123/14,484 69% improvement All studies 69% 0.31 [0.21-0.44] 7/6,443 123/14,484 69% improvement 7 paxlovid COVID-19 mortality results c19early.com/pl Sep 2022 Tau​2 = 0.02, I​2 = 4.8%, p < 0.0001 Favors paxlovid Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wong (PSM) 3% 0.97 [0.31-3.03] 890 (n) 890 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.96 Early treatment 3% 0.97 [0.31-3.03] 0/890 0/890 3% improvement All studies 3% 0.97 [0.33-2.86] 0/890 0/890 3% improvement 1 paxlovid COVID-19 mechanical ventilation result c19early.com/pl Sep 2022 Tau​2 = 0.00, I​2 = 0.0%, p = 0.96 Favors paxlovid Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pfizer (DB RCT) 86% 0.14 [0.01-2.75] 0/576 3/569 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.2 Early treatment 86% 0.14 [0.01-2.75] 0/576 3/569 86% improvement All studies 86% 0.14 [0.01-2.75] 0/576 3/569 86% improvement 1 paxlovid COVID-19 ICU result c19early.com/pl Sep 2022 Tau​2 = 0.00, I​2 = 0.0%, p = 0.2 Favors paxlovid Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Hammond (DB RCT) 88% 0.12 [0.06-0.26] hosp. 8/1,039 65/1,046 Improvement, RR [CI] Treatment Control Wong (PSM) 4% 0.96 [0.88-1.04] hosp. time 890 (n) 890 (n) Yip (PSW) 21% 0.79 [0.65-0.95] hosp. Arbel 65+ 73% 0.27 [0.15-0.49] hosp. Arbel 40-64 26% 0.74 [0.35-1.58] hosp. Dryden-Peterson 45% 0.55 [0.38-0.80] hosp. 40/6,036 232/24,286 Ganatra (PSM) 56% 0.44 [0.21-0.91] hosp. 10/1,130 23/1,130 Zhou (PSM) 84% 0.16 [0.11-0.22] hosp. 34/2,808 752/10,849 Tau​2 = 0.35, I​2 = 94.9%, p = 0.00031 Early treatment 59% 0.41 [0.26-0.67] 92/11,903 1,072/38,201 59% improvement All studies 59% 0.41 [0.26-0.67] 92/11,903 1,072/38,201 59% improvement 8 paxlovid COVID-19 hospitalization results c19early.com/pl Sep 2022 Tau​2 = 0.35, I​2 = 94.9%, p = 0.00031 Favors paxlovid Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Hammond (DB RCT) 96% 0.04 [0.00-0.68] death 0/1,039 12/1,046 Improvement, RR [CI] Treatment Control Wong (PSM) 66% 0.34 [0.23-0.50] death 890 (n) 890 (n) Yip (PSW) 19% 0.81 [0.47-1.39] death/ICU Arbel 65+ 79% 0.21 [0.05-0.82] death Arbel 40-64 -32% 1.32 [0.16-10.8] death Najjar-Debbiny 46% 0.54 [0.39-0.75] severe case Pfizer (DB RCT) 67% 0.33 [0.01-8.13] death 0/576 1/569 Dryden-Peterson 45% 0.55 [0.38-0.80] hosp. 40/6,036 232/24,286 Ganatra (PSM) 95% 0.05 [0.00-0.81] death 0/1,130 10/1,130 Zhou (PSM) 73% 0.27 [0.13-0.58] death 7/2,808 100/10,849 Tau​2 = 0.11, I​2 = 54.0%, p < 0.0001 Early treatment 55% 0.45 [0.32-0.63] 47/12,479 355/38,770 55% improvement All studies 55% 0.45 [0.32-0.63] 47/12,479 355/38,770 55% improvement 10 paxlovid COVID-19 serious outcomes c19early.com/pl Sep 2022 Tau​2 = 0.11, I​2 = 54.0%, p < 0.0001 Effect extraction pre-specified(most serious outcome) Favors paxlovid Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Zhong 15% 0.85 [0.65-1.13] recov. time 106 (n) 36 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.26 Early treatment 15% 0.85 [0.65-1.13] 0/106 0/36 15% improvement All studies 15% 0.85 [0.65-1.13] 0/106 0/36 15% improvement 1 paxlovid COVID-19 recovery result c19early.com/pl Sep 2022 Tau​2 = 0.00, I​2 = 0.0%, p = 0.26 Favors paxlovid Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pfizer (DB RCT) 37% 0.63 [0.40-1.00] cases 986 (n) 985 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.05 Prophylaxis 37% 0.63 [0.40-1.00] 0/986 0/985 37% improvement All studies 37% 0.63 [0.40-1.00] 0/986 0/985 37% improvement 1 paxlovid COVID-19 case result c19early.com/pl Sep 2022 Tau​2 = 0.00, I​2 = 0.0%, p = 0.05 Favors paxlovid Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wong (PSM) 28% 0.72 [0.56-0.93] viral+ 890 (n) 890 (n) Improvement, RR [CI] Treatment Control Shao 20% 0.80 [0.71-0.91] viral time 17 (n) 114 (n) OT​1 Li (ES) 79% 0.21 [0.15-0.28] viral+ 18/175 130/224 Lu 12% 0.88 [0.78-0.98] viral+ n/a n/a Shao 20% 0.80 [0.71-0.91] viral time 17 (n) 114 (n) OT​1 Zhong 16% 0.84 [0.74-0.96] viral time 106 (n) 36 (n) Tau​2 = 0.04, I​2 = 87.0%, p = 0.00029 Early treatment 28% 0.72 [0.60-0.86] 18/1,205 130/1,378 28% improvement Li 32% 0.68 [0.47-0.98] viral+ 40/83 130/224 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.0025 Late treatment 32% 0.68 [0.47-0.98] 40/83 130/224 32% improvement All studies 18% 0.82 [0.77-0.87] 58/1,288 260/1,602 18% improvement 7 paxlovid COVID-19 viral clearance results c19early.com/pl Sep 2022 Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 1 OT: comparison with other treatment Favors paxlovid Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Hammond (DB RCT) 96% 0.04 [0.00-0.68] death 0/1,039 12/1,046 Improvement, RR [CI] Treatment Control Pfizer (DB RCT) 67% 0.33 [0.01-8.13] death 0/576 1/569 Tau​2 = 0.00, I​2 = 0.0%, p = 0.034 Early treatment 90% 0.10 [0.01-0.84] 0/1,615 13/1,615 90% improvement Pfizer (DB RCT) 37% 0.63 [0.40-1.00] cases 986 (n) 985 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.05 Prophylaxis 37% 0.63 [0.40-1.00] 0/986 0/985 37% improvement All studies 69% 0.31 [0.06-1.53] 0/2,601 13/2,600 69% improvement 3 paxlovid COVID-19 Randomized Controlled Trials c19early.com/pl Sep 2022 Tau​2 = 1.01, I​2 = 45.5%, p = 0.15 Effect extraction pre-specified(most serious outcome) Favors paxlovid Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Hammond (DB RCT) 96% 0.04 [0.00-0.68] 0/1,039 12/1,046 Improvement, RR [CI] Treatment Control Pfizer (DB RCT) 67% 0.33 [0.01-8.13] 0/576 1/569 Tau​2 = 0.00, I​2 = 0.0%, p = 0.034 Early treatment 90% 0.10 [0.01-0.84] 0/1,615 13/1,615 90% improvement All studies 90% 0.10 [0.01-0.84] 0/1,615 13/1,615 90% improvement 2 paxlovid COVID-19 RCT mortality results c19early.com/pl Sep 2022 Tau​2 = 0.00, I​2 = 0.0%, p = 0.034 Favors paxlovid Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Hammond (DB RCT) 96% 0.04 [0.00-0.68] death 0/1,039 12/1,046 Improvement, RR [CI] Treatment Control Wong (PSM) 66% 0.34 [0.23-0.50] death 890 (n) 890 (n) Yip (PSW) 19% 0.81 [0.47-1.39] death/ICU Arbel 65+ 79% 0.21 [0.05-0.82] death Arbel 40-64 -32% 1.32 [0.16-10.8] death Najjar-Debbiny 46% 0.54 [0.39-0.75] severe case Li (ES) 79% 0.21 [0.15-0.28] viral+ 18/175 130/224 Lu 12% 0.88 [0.78-0.98] viral+ n/a n/a Ganatra (PSM) 95% 0.05 [0.00-0.81] death 0/1,130 10/1,130 Shao 20% 0.80 [0.71-0.91] viral time 17 (n) 114 (n) OT​1 Zhong 15% 0.85 [0.65-1.13] recov. time 106 (n) 36 (n) Tau​2 = 0.13, I​2 = 86.1%, p < 0.0001 Early treatment 45% 0.55 [0.41-0.73] 18/3,357 152/3,440 45% improvement Li 32% 0.68 [0.47-0.98] viral+ 40/83 130/224 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.0025 Late treatment 32% 0.68 [0.47-0.98] 40/83 130/224 32% improvement All studies 34% 0.66 [0.54-0.81] 58/3,440 282/3,664 34% improvement 12 paxlovid COVID-19 peer reviewed trials c19early.com/pl Sep 2022 Tau​2 = 0.06, I​2 = 75.0%, p < 0.0001 Effect extraction pre-specified(most serious outcome) 1 OT: comparison with other treatment Favors paxlovid Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Hammond (DB RCT) 96% 0.04 [0.00-0.68] death 0/1,039 12/1,046 Improvement, RR [CI] Treatment Control Hammond (DB RCT) 95% 0.05 [0.00-0.89] death 0/697 9/682 Hammond (DB RCT) 88% 0.12 [0.06-0.26] hosp. 8/1,039 65/1,046 Hammond (DB RCT) 89% 0.11 [0.04-0.28] hosp. 5/697 44/682 Wong (PSM) 66% 0.34 [0.23-0.50] death 890 (n) 890 (n) Wong (PSM) 3% 0.97 [0.31-3.03] ventilation 890 (n) 890 (n) Wong (PSM) 43% 0.57 [0.45-0.72] progression 890 (n) 890 (n) Wong (PSM) 4% 0.96 [0.88-1.04] hosp. time 890 (n) 890 (n) Wong (PSM) 28% 0.72 [0.56-0.93] viral+ 890 (n) 890 (n) Yip (PSW) 19% 0.81 [0.47-1.39] death/ICU Yip (PSW) 21% 0.79 [0.65-0.95] hosp. Arbel 65+ 79% 0.21 [0.05-0.82] death Arbel 65+ -32% 1.32 [0.16-10.8] death Arbel 65+ 73% 0.27 [0.15-0.49] hosp. Arbel 65+ 26% 0.74 [0.35-1.58] hosp. Arbel 40-64 -32% 1.32 [0.16-10.8] death Arbel 40-64 26% 0.74 [0.35-1.58] hosp. Najjar-Debbiny 46% 0.54 [0.39-0.75] severe case Pfizer (DB RCT) 67% 0.33 [0.01-8.13] death 0/576 1/569 Pfizer (DB RCT) 86% 0.14 [0.01-2.75] ICU 0/576 3/569 Pfizer (DB RCT) 51% 0.49 [0.17-1.44] death/hosp. 5/576 10/569 Dryden-Peterson 45% 0.55 [0.38-0.80] hosp. 40/6,036 232/24,286 Shao 20% 0.80 [0.71-0.91] viral time 17 (n) 114 (n) OT​1 Li (ES) 79% 0.21 [0.15-0.28] viral+ 18/175 130/224 Li (ES) 41% 0.59 [0.50-0.69] viral time 175 (n) 224 (n) Lu 12% 0.88 [0.78-0.98] viral+ n/a n/a Ganatra (PSM) 95% 0.05 [0.00-0.81] death 0/1,130 10/1,130 Ganatra (PSM) 39% 0.61 [0.42-0.70] progression 89/1,130 163/1,130 Ganatra (PSM) 33% 0.67 [0.52-0.87] progression 89/1,130 163/1,130 Ganatra (PSM) 56% 0.44 [0.21-0.91] hosp. 10/1,130 23/1,130 Shao 20% 0.80 [0.71-0.91] viral time 17 (n) 114 (n) OT​1 Zhong 15% 0.85 [0.65-1.13] recov. time 106 (n) 36 (n) Zhong 16% 0.84 [0.74-0.96] viral time 106 (n) 36 (n) Zhong 16% 0.84 [0.76-0.93] viral time 106 (n) 36 (n) Zhou (PSM) 73% 0.27 [0.13-0.58] death 7/2,808 100/10,849 Zhou (PSM) 75% 0.25 [0.10-0.61] death 5/2,808 78/10,849 Zhou (PSM) 84% 0.16 [0.11-0.22] hosp. 34/2,808 752/10,849 Zhou (PSM) 89% 0.11 [0.07-0.17] hosp. 22/2,808 708/10,849 Li 32% 0.68 [0.47-0.98] viral+ 40/83 130/224 Pfizer (DB RCT) 37% 0.63 [0.40-1.00] cases 986 (n) 985 (n) Pfizer (DB RCT) 32% 0.68 [0.46-1.00] cases 986 (n) 985 (n) paxlovid COVID-19 outcomes c19early.com/pl Sep 2022 1 OT: comparison with other treatment Favors paxlovid Favors control
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit